Cargando…

Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort

PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 (“elderly”). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to questio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dao Trong, P., Gluszak, M., Reuss, D., von Deimling, A., Wick, A., König, L., Debus, J., Herold-Mende, C., Unterberg, A., Jungk, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992027/
https://www.ncbi.nlm.nih.gov/pubmed/36648586
http://dx.doi.org/10.1007/s11060-022-04230-1
_version_ 1784902258700320768
author Dao Trong, P.
Gluszak, M.
Reuss, D.
von Deimling, A.
Wick, A.
König, L.
Debus, J.
Herold-Mende, C.
Unterberg, A.
Jungk, C.
author_facet Dao Trong, P.
Gluszak, M.
Reuss, D.
von Deimling, A.
Wick, A.
König, L.
Debus, J.
Herold-Mende, C.
Unterberg, A.
Jungk, C.
author_sort Dao Trong, P.
collection PubMed
description PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 (“elderly”). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3. METHODS: Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes. RESULTS: 207 patients were included, among those 21 elderlies (10%). PFS was comparable between elderly and younger patients (46 vs. 54 months; p = 0.634). Oligodendroglioma was more common in the elderly (76% vs. 46%; p = 0.011). Most patients underwent tumor resection (elderly: 81% vs. younger: 91%; p = 0.246) yielding comparable residual tumor volumes (elderly: 7.8 cm(3); younger: 4.1 cm(3); p = 0.137). Adjuvant treatment was administered in 76% of elderly and 61% of younger patients (p = 0.163). Uni- and multi-variate survival analyses identified a tumor crossing the midline, surgical strategy, and pre- and post-operative tumor volumes as prognostic factors. CONCLUSION: Elderly patients constitute a small fraction of molecularly characterized LGGs. In contrast to previous reports, favorable surgical and survival outcomes were achieved in our series comparable to those of younger patients. Thus, intensified treatment including maximal safe resection should be advocated in elderly patients whenever feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04230-1.
format Online
Article
Text
id pubmed-9992027
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-99920272023-03-09 Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort Dao Trong, P. Gluszak, M. Reuss, D. von Deimling, A. Wick, A. König, L. Debus, J. Herold-Mende, C. Unterberg, A. Jungk, C. J Neurooncol Case Study PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 (“elderly”). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3. METHODS: Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes. RESULTS: 207 patients were included, among those 21 elderlies (10%). PFS was comparable between elderly and younger patients (46 vs. 54 months; p = 0.634). Oligodendroglioma was more common in the elderly (76% vs. 46%; p = 0.011). Most patients underwent tumor resection (elderly: 81% vs. younger: 91%; p = 0.246) yielding comparable residual tumor volumes (elderly: 7.8 cm(3); younger: 4.1 cm(3); p = 0.137). Adjuvant treatment was administered in 76% of elderly and 61% of younger patients (p = 0.163). Uni- and multi-variate survival analyses identified a tumor crossing the midline, surgical strategy, and pre- and post-operative tumor volumes as prognostic factors. CONCLUSION: Elderly patients constitute a small fraction of molecularly characterized LGGs. In contrast to previous reports, favorable surgical and survival outcomes were achieved in our series comparable to those of younger patients. Thus, intensified treatment including maximal safe resection should be advocated in elderly patients whenever feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04230-1. Springer US 2023-01-17 2023 /pmc/articles/PMC9992027/ /pubmed/36648586 http://dx.doi.org/10.1007/s11060-022-04230-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Study
Dao Trong, P.
Gluszak, M.
Reuss, D.
von Deimling, A.
Wick, A.
König, L.
Debus, J.
Herold-Mende, C.
Unterberg, A.
Jungk, C.
Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
title Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
title_full Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
title_fullStr Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
title_full_unstemmed Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
title_short Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
title_sort isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
topic Case Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992027/
https://www.ncbi.nlm.nih.gov/pubmed/36648586
http://dx.doi.org/10.1007/s11060-022-04230-1
work_keys_str_mv AT daotrongp isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT gluszakm isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT reussd isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT vondeimlinga isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT wicka isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT konigl isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT debusj isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT heroldmendec isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT unterberga isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort
AT jungkc isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort